Atrial fibrillation following investigation of rhythm management: AFFIRM trial outcomes. What might be their implications for arrhythmia control?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 3, 2002, Pages 131-133

  Singh, Bramah N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; PROPAFENONE; QUINIDINE; SOTALOL;

AGED; CONTROLLED STUDY; EDITORIAL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; SCREENING; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0036664607     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700301     Document Type: Editorial

References (17)

1. Movsowitz C, Marchlinski FE. Interactions between implantable cardioverter-defibrillators and class III antiarrhythmic drugs. Am J Cardiol 82:411, 1998
2. Prystowsky EN, Benson D, Woodrow M, et al. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 93(6):1262-1277, 1996
3. Jung F, DiMarco JP. MD. Treatment strategies for atrial fibrillation. Am J Med 104(3):272-286
4. Jais P, Haissaguerre M, Shah DC. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 95:572-576, 1997
5. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998
6. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 58:59-70, 1959
7. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 140:183-188, 1962
8. Singh BN, Vaghaiwalla Mody F, Lopez B, Sarma JSM. Antiarrhythmic agents for atrial fibrillation: Focus on prolong atrial repolarization. Am J Cardiol 84:161R-173R, 1999
9. Singh BN. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10:83-301, 1999
10. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on Class III actions. Am J Cardiol 84(9A):11-19, 1999
11. Lazzara R. From first class to third class: Recent upheaval in antiarrhythmic therapy - Lessons from clinical trials. Am J Cardiol 78:28-33, 1996
12. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs. Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6:920-936, 1995
13. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 78:41-53, 1996
14. Singh BN. What niche will newer class III antiarrhythmic drugs occupy? Current Cardiology Reports 3:314-323, 2001
15. Roy D, Talajic M, Dorian P, et al, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913-918, 2000
16. The AFFIRM Investigators. Atrial fibrillation following investigation of rhythm management: AFFIRM Study Design. Am J Cardiol 79:1198-1204, 1997
17. Mason JW, ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329:452-462, 1993 135-137